Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Oncology  |  Rheumatology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Sarcoma Clinical Trials

A listing of Sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (14) clinical trials

Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)

This is a Phase 1b, multi-site, open-label, non-randomized clinical trial evaluating the safety, tolerability, and pharmacokinetics of escalating doses of olaparib and trabectedin in patients with unresectable advanced/metastatic sarcomas. Patients will continue to be treated on this combination regimen in the absence of disease progression, intolerable toxicity or patient's decision.


Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea

Follicular lymphoma is the second most common non-Hodgkin's lymphoma in Western countries, but it is relatively less frequent in Asia. As a result, the prognosis and treatment status in Korean patients with follicular lymphoma have been rarely studied. With the recent addition of monoclonal antibodies targeting CD20 into existing cytotoxic ...

Phase N/A

Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients

Gliomas are the most common primary intra-axial brain tumors arising from the glial cells. The reference treatment consists in a surgical removal followed by radiotherapy and chemotherapy (Temozolomide). Because of frequent recurrences after first-line therapy, an accurate neuroimaging is needed. The reference anatomical modality is represented by Magnetic Resonance Imaging ...

Phase N/A

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Background Gene-expression profiling (GEP) has identified two dominant molecular subtypes,activated B cell like (ABC) and germinal center B cell like (GCB), that arise by distinct mechanisms, have distinct prognoses, and respond differently to targeted therapy Recently, genetic subtypes of DLBCL have been described within molecular subtypes that have distinct genotypic, ...


Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Na ve Follicular Lymphoma

The study will assess the safety and efficacy of umbralisib in combination with ublituximab in subjects with treatment nave Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL). Ublituximab will be administered through Cycle 12, while umbralisib will be administered through cycle 24. After this time, subjects will be followed for ...


Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

This is a study of genetically engineered ADP-A2M4 in HLA-A*02 subjects with metastatic or inoperable (advanced) Synovial Sarcoma or MRCLS who have received prior chemotherapy and whose tumor expresses the MAGE-A4 tumor antigen.


A Study to Evaluate the Safety Tolerability Pharmacokinetics (PK) Pharmacodynamics (PD) and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

In the Phase Ia part of the study, tiragolumab is administered as a single agent in participants with R/R MM or R/R NHL. In the Phase Ib part of the study, tiragolumab is administered in combination with daratumumab in participants with R/R MM or with rituximab in participants with R/R ...


Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

PRIMARY OBJECTIVES: I. To determine the rate of completion of 4 planned high dose methotrexate (HDMTX) doses when glucarpidase is administered after each dose. SECONDARY OBJECTIVES: I. To assess the length of hospital stay (LOS) associated with methotrexate (MTX)-related adverse events (AEs) following administration of glucarpidase 24 hours after HDMTX. ...

Phase N/A

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patient

This is a single-arm trial that will evaluate the feasibility and toxicities of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment.


Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance (1-4). Up to 20% of individuals in the general population acquire mutations in their bone marrow stem cells as they age that give that population of cells a survival or 'clonal' advantage for growth. The frequency of CHIP may be higher in ...

Phase N/A